The 2015 'mini-HA' study established that a rationally designed, stable trimeric influenza hemagglutinin (HA) stem immunogen can elicit broadly reactive antibodies and protect mice and macaques, while explicitly deferring the questions of the minimal antigen and adjuvant doses required for protection and of the effect of pre-existing human influenza immunity on elicited breadth, which — because no animal model recapitulates complex human immunity — requires translation to humans through clinical studies; framing itself as a group-1 proof of concept, it also acknowledged that the elicited serum showed the expected low reactivity to group 2 HAs, raising the further question of whether the same design principles could yield stem immunogens with robust group 2 or pan-influenza breadth. A decade of follow-up has substantially narrowed this gap: first-in-human studies have shown safety and broad immunogenicity for a group-1 mini-HA descendant (phase 1/2a, 45–135 µg with or without alum), a group-1 stem ferritin nanoparticle (H1ssF), and a group-2 stem nanoparticle (H10ssF); co-immunization with group-1 and group-2 stem immunogens achieves cross-group protection in animals; and human immune imprinting has been shown to blunt stem responses in defined settings. What remains open is the clinical core of the original question: no HA-stem vaccine has demonstrated protection against human influenza infection or disease, no stem-specific correlate of protection exists, no combined group-1 plus group-2 regimen has been tested in humans, and the modulation of stem-elicited breadth by pre-existing immunity across age groups, as well as the minimal protective doses, remain undefined. Solving this problem means completing the clinical proof of the stem-immunogen vaccine concept.

Background

Influenza A viruses are a persistent global health burden whose vaccines must be reformulated almost annually. The principal antibody target is hemagglutinin (HA), a trimeric surface glycoprotein in which each monomer comprises a membrane-distal 'head' domain that binds sialylated receptors on host cells and a membrane-proximal 'stem' domain that drives fusion of viral and endosomal membranes. The head is immunodominant but mutates rapidly (antigenic drift), whereas the stem is far more conserved. Influenza A HAs divide into two phylogenetic groups — group 1 (including H1, H2, H5, H6, H9) and group 2 (including H3, H4, H7, H10) — and the seasonal vaccine contains strains from both. Starting around 2008–2011, human broadly neutralizing antibodies (bnAbs) were discovered that bind the HA stem and neutralize many subtypes; most are restricted to one group, and their protective activity in vivo involves not only neutralization but also Fc-mediated effector functions such as antibody-dependent cellular cytotoxicity (ADCC), the killing of infected cells by NK cells engaged through the antibody Fc region. Protection by licensed vaccines is classically correlated with hemagglutination-inhibition (HAI) titers, an assay that measures head-binding antibodies and is therefore not informative for stem-directed immunity; the HA stem has no established correlate of protection in humans. A further human-specific complication is immune imprinting: the first influenza exposures bias subsequent antibody responses toward the initially encountered HA, shaping (and often limiting) responses to later vaccination in an age-dependent way.

In this landscape, Impagliazzo and colleagues (2015) reported the rational design of 'mini-HAs': soluble, stable, trimeric stem-only immunogens derived from an H1 (group 1) sequence, in which the immunodominant head is removed and the stem is stabilized by engineering. The lead construct bound human bnAbs, protected mice against lethal heterologous and heterosubtypic challenge, reduced fever after sublethal challenge in cynomolgus monkeys, and elicited antibodies that bound diverse HAs, neutralized H5N1, and mediated ADCC. The authors explicitly framed the result as a group-1 proof of concept and enumerated what remained unresolved: the in vivo studies used a single antigen dose and a potent adjuvant not registered for human use, so 'future studies will need to address the minimal doses of mini-HA and adjuvant for a protective response'; because pre-existing immunity may profoundly affect the breadth of the response and no animal model recapitulates complex human immunity, 'such studies should be performed in humans'; the elicited serum showed the expected low reactivity to group 2 HAs, reflecting structural differences between group-1 and group-2 stems that restrict most bnAbs to one group; and clinical translation would require human studies of safety, immunogenicity, dosing, and breadth.

The decade since has seen this design space expand into several clinical-stage stem immunogen families: the mini-HA lineage itself (soluble stabilized stem trimers), stem domains displayed on self-assembling ferritin nanoparticles (H1ssF for group 1, H10ssF for group 2, where ferritin is a bacterial iron-storage protein engineered to array antigens in repetitive spikes), chimeric HAs pairing divergent heads with conserved stems, and germline-targeting immunogens designed to engage the precursor B-cell receptors of desired bnAb lineages. Human safety and immunogenicity data now exist for group-1 and group-2 stem components separately, and animal co-immunization achieves cross-group breadth. The unresolved question is whether these components can be combined into a regimen that demonstrably protects humans against heterosubtypic influenza A across both groups, under a defined dose, adjuvant, and schedule, and despite or by modulating pre-existing imprinted immunity.

Problem Statement

Determine whether vaccination with HA-stem immunogens can protect humans against heterosubtypic influenza A infection and disease across both phylogenetic groups, and establish the conditions under which it does. Concretely, building on the mini-HA proof of concept and the first-in-human safety/immunogenicity data now available for group-1 and group-2 stem components: (1) assess the existing evidence on whether a stem-immunogen regimen protects humans and specify the controlled human influenza challenge or field-efficacy study — together with the stem-specific correlate assay and protection endpoint — that would demonstrate or refute protective efficacy (the licensed HAI correlate measures head antibodies and is inapplicable); (2) define a regimen — dose, adjuvant, schedule, and antigen design — that elicits responses covering both influenza A groups (with influenza B coverage the recognized further extension), since group-1-only vaccination in humans produces no meaningful H3 response and cross-group breadth has so far been achieved only by animal co-immunization; (3) characterize how pre-existing, imprinted influenza immunity modulates the magnitude, breadth, and durability of stem-elicited responses across human age groups, and whether vaccination can override group-biased imprinting; and (4) define the minimal antigen and adjuvant doses required for a protective response in the relevant host populations — the protection-anchored minimum judged against the protection endpoint or correlate of (1), as distinct from the breadth-oriented dose range examined in (2). (1)–(4) jointly constitute one objective — completing the clinical proof of the stem-immunogen vaccine concept — and are scientifically interdependent: minimal doses and regimen comparisons presuppose a protection endpoint or correlate, and breadth claims in any population must be interpreted against that population's immune history. Because the corresponding human efficacy and correlate data do not yet exist, the gaps in (1)–(4) must be closed by argument from the existing evidence and by specification of the regimen and study conditions each would require.

References

  1. Impagliazzo A, Milder F, Kuipers H, Wagner MV, Zhu X, Hoffman RMB, et al. A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. Science 349, 1301–1306 (2015). doi:10.1126/science.aac7263. https://doi.org/10.1126/science.aac7263
  2. Hertoghs N, Tang C, van Paassen V, Jongeneelen M, Tolboom J, Yieh L, et al. A group 1 hemagglutinin stem vaccine elicits broad humoral responses against influenza in phase 1/2a study. Nature Communications 17, 3451 (2026). doi:10.1038/s41467-026-70396-1. https://doi.org/10.1038/s41467-026-70396-1
  3. Widge AT, Hofstetter AR, Houser KV, Awan SF, Chen GL, Burgos Florez MC, et al. An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults. Science Translational Medicine 15, eade4790 (2023). doi:10.1126/scitranslmed.ade4790. https://doi.org/10.1126/scitranslmed.ade4790
  4. Andrews SF, Cominsky LY, Shimberg GD, Gillespie RA, Gorman J, Raab JE, et al. An influenza H1 hemagglutinin stem-only immunogen elicits a broadly cross-reactive B cell response in humans. Science Translational Medicine 15, eade4976 (2023). doi:10.1126/scitranslmed.ade4976. https://doi.org/10.1126/scitranslmed.ade4976
  5. Houser KV, Chen GL, Carter C, Crank MC, Nguyen TA, Burgos Florez MC, et al. Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial. Nature Medicine 28, 383–391 (2022). doi:10.1038/s41591-021-01660-8. https://doi.org/10.1038/s41591-021-01660-8
  6. Folschweiller N, Vanden Abeele C, Chu L, Van Damme P, García-Sastre A, Krammer F, et al. Reactogenicity, safety, and immunogenicity of chimeric haemagglutinin influenza split-virion vaccines, adjuvanted with AS01 or AS03 or non-adjuvanted: a phase 1-2 randomised controlled trial. The Lancet Infectious Diseases 22, 1062–1075 (2022). doi:10.1016/s1473-3099(22)00024-x. https://doi.org/10.1016/s1473-3099(22)00024-x
  7. Casazza JP, Hofstetter AR, Costner PJM, Holman LA, Hendel CS, Widge AT, et al. Phase 1 dose-escalation trial evaluating a group 2 influenza hemagglutinin stabilized stem nanoparticle vaccine. npj Vaccines 9, 171 (2024). doi:10.1038/s41541-024-00959-0. https://doi.org/10.1038/s41541-024-00959-0
  8. Mantus GE, Chopde AJ, Gorman J, Cominsky LY, Ourahmane A, Creanga A, et al. Vaccination with different group 2 influenza subtypes alters epitope targeting and breadth of hemagglutinin stem-specific human B cells. Science Translational Medicine 17, eadr8373 (2025). doi:10.1126/scitranslmed.adr8373. https://doi.org/10.1126/scitranslmed.adr8373
  9. Sutton TC, Chakraborty S, Mallajosyula VVA, Lamirande EW, et al. Protective efficacy of influenza group 2 hemagglutinin stem-fragment immunogen vaccines. npj Vaccines 2, 35 (2017). doi:10.1038/s41541-017-0036-2. https://doi.org/10.1038/s41541-017-0036-2
  10. Corbett KS, Moin SM, Yassine HM, Cagigi A, et al. Design of Nanoparticulate Group 2 Influenza Virus Hemagglutinin Stem Antigens That Activate Unmutated Ancestor B Cell Receptors of Broadly Neutralizing Antibody Lineages. mBio 10, e02810-18 (2019). doi:10.1128/mbio.02810-18. https://doi.org/10.1128/mbio.02810-18
  11. Darricarrère N, Qiu Y, Kanekiyo M, Creanga A, Gillespie RA, Moin SM, et al. Broad neutralization of H1 and H3 viruses by adjuvanted influenza HA stem vaccines in nonhuman primates. Science Translational Medicine 13, eabe5449 (2021). doi:10.1126/scitranslmed.abe5449. https://doi.org/10.1126/scitranslmed.abe5449
  12. Moin SM, Boyington JC, Boyoglu-Barnum S, Gillespie RA, Cerutti G, Cheung CS, et al. Co-immunization with hemagglutinin stem immunogens elicits cross-group neutralizing antibodies and broad protection against influenza A viruses. Immunity 55, 2405–2418 (2022). doi:10.1016/j.immuni.2022.10.015. https://doi.org/10.1016/j.immuni.2022.10.015
  13. Ray R, Nait Mohamed FA, Maurer DP, Huang J, Alpay BA, Ronsard L, et al. Eliciting a single amino acid change by vaccination generates antibody protection against group 1 and group 2 influenza A viruses. Immunity 57, 1141–1159 (2024). doi:10.1016/j.immuni.2024.03.022. https://doi.org/10.1016/j.immuni.2024.03.022
  14. van der Lubbe JEM, Verspuij JWA, Huizingh J, Schmit-Tillemans SPR, et al. Mini-HA Is Superior to Full Length Hemagglutinin Immunization in Inducing Stem-Specific Antibodies and Protection Against Group 1 Influenza Virus Challenges in Mice. Frontiers in Immunology 9, 2350 (2018). doi:10.3389/fimmu.2018.02350. https://doi.org/10.3389/fimmu.2018.02350
  15. Swart M, Kuipers H, Milder F, Jongeneelen M, Ritschel T, Tolboom J, et al. Enhancing breadth and durability of humoral immune responses in non-human primates with an adjuvanted group 1 influenza hemagglutinin stem antigen. npj Vaccines 8, 176 (2023). doi:10.1038/s41541-023-00772-1. https://doi.org/10.1038/s41541-023-00772-1
  16. Park JK, Han A, Czajkowski L, Reed S, et al. Evaluation of Preexisting Anti-Hemagglutinin Stalk Antibody as a Correlate of Protection in a Healthy Volunteer Challenge with Influenza A/H1N1pdm Virus. mBio 9, e02284-17 (2018). doi:10.1128/mbio.02284-17. https://doi.org/10.1128/mbio.02284-17
  17. Ng S, Nachbagauer R, Balmaseda A, Stadlbauer D, Ojeda S, Patel M, et al. Novel correlates of protection against pandemic H1N1 influenza A virus infection. Nature Medicine 25, 962–967 (2019). doi:10.1038/s41591-019-0463-x. https://doi.org/10.1038/s41591-019-0463-x
  18. Aydillo T, Escalera A, Strohmeier S, Aslam S, Sanchez-Cespedes J, Ayllon J, et al. Pre-existing Hemagglutinin Stalk Antibodies Correlate with Protection of Lower Respiratory Symptoms in Flu-Infected Transplant Patients. Cell Reports Medicine 1, 100130 (2020). doi:10.1016/j.xcrm.2020.100130. https://doi.org/10.1016/j.xcrm.2020.100130
  19. Dugan HL, Guthmiller JJ, Arevalo P, Huang M, et al. Preexisting immunity shapes distinct antibody landscapes after influenza virus infection and vaccination in humans. Science Translational Medicine 12, eabd3601 (2020). doi:10.1126/scitranslmed.abd3601. https://doi.org/10.1126/scitranslmed.abd3601
  20. Linderman SL, Ellebedy AH, Davis C, Eberhardt CS, et al. Influenza Immunization in the Context of Preexisting Immunity. Cold Spring Harbor Perspectives in Medicine 11, a040964 (2021). doi:10.1101/cshperspect.a040964. https://doi.org/10.1101/cshperspect.a040964
  21. Crofts KF, Holbrook BC, Page CL, Gillespie RA, D'Agostino RB Jr, Sangesland M, et al. Antibody function predicts viral control in newborn monkeys immunised with an influenza virus HA stem nanoparticle. Nature Communications 16, 3785 (2025). doi:10.1038/s41467-025-59149-8. https://doi.org/10.1038/s41467-025-59149-8